Elutia (ELUT) Q3 2026 Earnings Call Transcript
Elutia Inc. Q3 2026 Earnings Call Summary
Elutia Inc. (ELUT) Q3 2026 Earnings Call Transcript
Elutia Inc (ELUT) Q3 2026 Earnings Call Highlights: Cardiovascular Growth and NXT-41X Momentum ...
Elutia Reports Third Quarter 2026 Results: As Plastic Surgeons Cite Infection Risk in Every Breast Research Session During National Meeting, NXT-41x Heads to FDA This Quarter, Fully Funded Through Launch
Elutia Q3 2026 Earnings Call Transcript
Elutia to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026
Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
Elutia Obtains $8M Payment from Boston Scientific; Co. Now Fully Funded into 2029
Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th
Elutia to Participate in the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference & the H.C. Wainwright 28th Annual Global Investment Conference
Elutia (ELUT) Q2 2026 Earnings Call Transcript
Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch
Elutia Inc. 2026 Q2 - Results - Earnings Call Presentation
Elutia Inc. Q2 2026 Earnings Call Summary
Elutia Inc (ELUT) (Q2 2026) Earnings Call Highlights: Strategic Pivot to NXT41X Drives Strong ...
Elutia Inc. (ELUT) Q2 2026 Earnings Call Transcript
Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results
Elutia Secures $15 Million Loan Financing from Avenue Capital Group to Fund NXT-41x Launch in $1.5 Billion Plastic and Reconstructive Surgery Market
Elutia Q2 2026 Earnings Call Transcript
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.